Celadon Pharmaceuticals (CEL) Competitors GBX 14.70 +0.20 (+1.38%) As of 06:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock CEL vs. CNSL, OTT, BCE, FOX, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Fox Marble (FOX), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Its Competitors Cambridge Nutritional Sciences Oxford Technology 3 Venture Capital Trust Beacon Energy Fox Marble Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Cambridge Nutritional Sciences (LON:CNSL) and Celadon Pharmaceuticals (LON:CEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Does the MarketBeat Community favor CNSL or CEL? Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users. CompanyUnderperformOutperformCambridge Nutritional SciencesN/AN/ACeladon PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes Which has stronger earnings and valuation, CNSL or CEL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCambridge Nutritional Sciences£9.77M0.77-£3.03MN/AN/ACeladon Pharmaceuticals£123.38K73.07-£4.97M-£7.98-1.84 Do institutionals and insiders hold more shares of CNSL or CEL? 10.2% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. 10.9% of Cambridge Nutritional Sciences shares are owned by company insiders. Comparatively, 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer CNSL or CEL? In the previous week, Celadon Pharmaceuticals had 2 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 2 mentions for Celadon Pharmaceuticals and 0 mentions for Cambridge Nutritional Sciences. Cambridge Nutritional Sciences' average media sentiment score of 0.00 beat Celadon Pharmaceuticals' score of -0.26 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the media. Company Overall Sentiment Cambridge Nutritional Sciences Neutral Celadon Pharmaceuticals Neutral Is CNSL or CEL more profitable? Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cambridge Nutritional Sciences-3.36% -3.34% -2.36% Celadon Pharmaceuticals -4,024.62%-187.26%-34.40% Which has more risk & volatility, CNSL or CEL? Cambridge Nutritional Sciences has a beta of 3.89, suggesting that its share price is 289% more volatile than the S&P 500. Comparatively, Celadon Pharmaceuticals has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. SummaryCambridge Nutritional Sciences beats Celadon Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£9.02M£2.15B£5.57B£2.92BDividend YieldN/A2.92%5.28%4.90%P/E Ratio-1.844.0227.14125.92Price / Sales73.07663.25419.32243,053.64Price / Cash3.0510.2538.2528.07Price / Book3.876.977.064.58Net Income-£4.97M£20.70B£3.23B£5.91B7 Day Performance22.50%-0.21%2.83%6.81%1 Month Performance194.00%5.27%9.02%16.55%1 Year Performance-81.51%105.11%31.36%78.04% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 14.70+1.4%N/A-85.3%£9.02M£123.38K-1.842,780News CoverageGap DownCNSLCambridge Nutritional SciencesN/AGBX 3.37+3.7%N/A-25.0%£8.02M£9.77M-362.103,200Gap DownOTTOxford Technology 3 Venture Capital TrustN/AN/AN/AN/A£2.13M-£85K-12.59203Gap DownBCEBeacon EnergyN/AGBX 0+33.3%N/A-63.6%£740KN/A-0.3544,600Gap UpHigh Trading VolumeFOXFox MarbleN/AGBX 0.04-4.4%N/A-97.0%£179K£722.06K-135.0010,600News CoverageGap DownCZNCurzon EnergyN/AN/AN/AN/A£34KN/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Cambridge Nutritional Sciences Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Fox Marble Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CEL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.